## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

- 1-4. (Canceled)
- 5. (Currently amended) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is  $-(CH_2)_bCH=CH(CH_2)_c$ -;

 $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is  $-R_3$ ,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,

 $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,

 $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,

 $-(CH_2)_bSO_dR_5$  or  $-(CH_2)_bSO_2NR_5R_6$ ;

b and c are the same or different and at each occurrence independently selected from [[0]], 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

 $R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkoxy,  $-C(=O)OR_8, -C(=O)R_8, -C(O)NR_8R_9, -C(=O)NR_8OR_9, -SO_2NR_8R_9, -NR_8SO_2R_9, -CN, -NO_2, -NR_8R_9, -NR_8C(=O)R_9, -NR_8C(=O)(CH_2)_bOR_9, -NR_8C(=O)(CH_2)_bR_9, -O(CH_2)_bNR_8R_9;$ 

 $R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

6. (Previously presented) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is  $-(CH_2)_bC \equiv C(CH_2)_c$ ;

 $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>(CH<sub>2</sub>)<sub>c</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)NR<sub>6</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>SO<sub>d</sub>R<sub>5</sub> or -(CH<sub>2</sub>)<sub>b</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>.

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

- R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;
- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.
- 7-9. (Canceled)
- 10. (Previously presented) A compound having the structure:

$$R_2$$
 $R_2$ 
 $R_2$ 
 $R_2$ 

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_{a^-}$ ,  $-(CH_2)_bCH=CH(CH_2)_{c^-}$ , or  $-(CH_2)_bC\equiv C(CH_2)_{c^-}$ ;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is -(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>5</sub>; a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ , -CN,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.
- 11. (Previously presented) A compound having the structure:

$$R_2$$
 $R_2$ 
 $A$ 
 $A$ 
 $R$ 

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC\equiv C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>; a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>,

 $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ , -CN,  $-NO_2$ ,  $-NR_8R_9$ ,

 $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,

 $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.
- 12. (Previously presented) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC\equiv C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is  $-(CH_2)_bNR_5C(=O)R_{6}$ ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR $_8$ , -C(=O)NR $_8$ R $_9$ ,

 $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ , -CN,  $-NO_2$ ,  $-NR_8R_9$ ,

 $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,

 $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

## 13. (Currently amended) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC=C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>R<sub>6</sub>;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from [[0]], 1, 2, 3 or 4;

heterocycle, heterocyclealkyl, substituted heterocyclealkyl,

 $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,

 $-NR_8SO_2R_9$ , -CN,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,

-NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

## 14-17. (Canceled)

18. (Previously presented)

A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC\equiv C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is  $R_4$ ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is 3-triazolyl, optionally substituted at its 5-position with:

- (a) a C<sub>1</sub>-C<sub>4</sub> straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
- (b) a 2-pyrrolidinyl group;
- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.
- 19. (Previously presented) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ ,  $-(CH_2)_bCH=CH(CH_2)_c$ , or  $-(CH_2)_bC\equiv C(CH_2)_c$ ;

 $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is  $R_4$ :

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>,

-O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is tetrazole;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

20. (Previously presented) A compound having the structure:

$$R_2$$
 $H$ 
 $N$ 
 $A \sim R_1$ 

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC\equiv C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

R<sub>2</sub> is R<sub>4:</sub>

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is imidazole;

- $R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

21-72. (Canceled)

## 73. (Currently amended)

A compound having the structure:

$$R_2$$
 $A$ 
 $R_1$ 

or a pharmaceutically acceptable salt thereof, wherein:

-A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy,  $-NR_8C(=O)R_9$ ,  $-C(=O)NR_8R_9$ , and  $-O(CH_2)_bNR_8R_9$ , wherein b is 2 or 3;

 $R_2$  is  $-(CH_2)_bC(=O)NR_5R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ , 3-triazolyl or 5-tetrazolyl, wherein b is 0.

a is 1, 2, 3, 4, 5 or 6;

c is at each occurrence 0, 1, 2, 3 or 4;

- R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;
- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and
- R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

# 74. (Previously presented) A compound having the structure:

or a pharmaceutically acceptable salt thereof, wherein:

-A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>) $_b$ NR<sub>8</sub>R<sub>9</sub>;

R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl:

a is 1, 2, 3, 4, 5 or 6;

*b* is 2 or 3;

c is at each occurrence 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

75-84. (Canceled)

85. (Previously presented) A compound having the structure:

$$R_2$$
 $R_2$ 
 $R_2$ 
 $R_1$ 

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a$ -,  $-(CH_2)_bCH=CH(CH_2)_c$ -, or  $-(CH_2)_bC\equiv C(CH_2)_c$ -;  $R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

 $R_2$  is  $R_4$ ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is 3-triazolyl, optionally substituted at its 5-position with:

- (a) methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl;
- R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

## 86-87. (Canceled)

- 88. (Previously presented) A composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.
- 89. (Previously presented) A composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.
- 90. (Previously presented) A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.
- 91. (Previously presented) A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier.
- 92. (Previously presented) A composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.
- 93. (Previously presented) A composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.

#### 94-97. (Canceled)

- 98. (Previously presented) A composition comprising the compound of claim 18 and a pharmaceutically acceptable carrier.
- 99. (Previously presented) A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.
- 100. (Previously presented) A composition comprising the compound of claim 20 and a pharmaceutically acceptable carrier.

- 101-102. (Canceled)
- 103. (Previously presented) A composition comprising the compound of claim 73 and a pharmaceutically acceptable carrier.
- 104. (Previously presented) A composition comprising the compound of claim 74 and a pharmaceutically acceptable carrier.
- 105. ((Previously presented) A composition comprising the compound of claim 85 and a pharmaceutically acceptable carrier.
- 106. (Previously presented) A compound of claim 6, wherein the compound is:
- 3-(2-phenylethynyl)-1H-indazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
- 107. (Previously presented) A compound of claim 10, wherein the compound is:
  - 1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl} piperidine-4-carboxylic acid;
  - 3-(4-fluorophenyl)(1H-indazol-5-yl) pyrrolidinyl ketone;
  - 3-(4-fluorophenyl)(1H-indazol-5-yl)piperazinyl ketone;
  - 1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;
- 1-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethan-1-one; or a pharmaceutically acceptable salt thereof.
- 108. (Previously presented) A compound of claim 11, wherein the compound is:
  - 3-(4-fluorophenyl)-1H-indazole-5-carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-benzamide;
  - N-(2-(dimethylamino)ethyl)3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;
  - methyl 4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoate;
  - 4-{3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoic acid;
  - 4-{(3-(4-fluorophenyl)-1H-indazole-5-yl)carbonylamino}benzamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridyl)carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridyl)carboxamide;

```
tert-butyl 3-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)propanoate;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxyphenyl)carboxamide;
      3-{(3-(4-fluorophenyl)-1H-Indazol-5-yl)carbonylamino)propanoic acid;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-nitrophenyl)carboxamide;
      tert-butyl-2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetate;
      4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino} butanoic acid;
      N-(3-aminophenyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
      2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetic acid;
      5-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino} pentanoic acid;
      4-({(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}methyl)benzoic acid;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridylmethyl)carboxamide;
      2-(4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}phenyl)acetic acid;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N,N-dimethylcarboxamide;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarboxamide;
      N-(3-aminoethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
      N-(3-aminopropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
      (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxypropyl)carboxamide;
      N-(2H-1,2,3,4-tetrazol-5-yl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
       {3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-morpholin-4-ylpropyl)carboxamide;
       (3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-pyridylmethyl)carboxamide;
       N-(((2R)-2-hydroxycyclohexyl)methyl)(3-(4-fluorophenyl)(1H-indazole-5-
yl)carboxamide;
       (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-(1-methylimidazol-5-
yl)ethyl)carboxamide);
       (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridylmethyl)carboxamide;
       N-(2-carbamoylethyl)(3 -(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
       N-(3-carbamoylpropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
       3-(4-methoxyphenyl)-1H-indazole-5-carboxamide;
       3-(4-hydroxyphenyl)-1H-indazole-5-carboxamide;
       3-(2-naphthyl)-1H-indazole-5-carboxamide;
       3-benzo(b)thiophen-2-yl-1H-indazole-5-carboxamide;
       3-benzo(d)furan-2-yl-1H-indazole-5-carboxamide;
```

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridyl)carboxamide;

```
3-(3-(methylethyl)phenyl)-1H-indazole-5-carboxamide;
```

- 3-(4-(dimethylamino)phenyl)-1H-indazole-5-carboxamide;
- 3-(3-furyl)-1H-indazole-5-carboxamide;
- 3-{4-(2-(dimethylamino)ethoxy)phenyl}-1H-indazole-5-carboxamide;
- 3-(3,4-dimethoxyphenyl)-1H-indazole-5-carboxamide;
- 3-(3-aminophenyl)-1H-indazole-5-carboxamide;
- 3-(2H-benzo(d)1,3-dioxolen-5-yl)-1H-indazole-5-carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(methylethyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-(dimethylamino)ethyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(4-(dimethylamino)butyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(3-(dimethylamino)propyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methylpropyl)carboxamide;
- (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-methylcarboxamide;
- 3-(3-(3-pyridylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
- 3-(3-(2-methoxyacetylamino)phenyl)-1H-indazole-5-carboxamide;
- 3-(3-(4-piperidylcarboxyamino)phenyl)-1H-indazole-5-carboxamide;
- (1S)-1-{N-(3-(5-carbamoyl(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;
- 3-{3-(2-methoxyethyl)amino)phenyl}-1H-indazole-5-carboxamide;
- 3-(3-(3-piperidylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;
- 3-(3-(2-furylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
- 3-{3-(2-(dimethylamino)acetylamino)phenyl}-1H-indazole-5-carboxamide;
- 3-(3-(2-phenylacetylamino)phenyl)-1H-Indazole-5-carboxamide;
- 3-{3-(2-(4-methoxyphenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
- 3-{3-(2-(2-methyl-1,3-thiazol-5-yl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-(3-(oxolan-3yl-carbonylamino)phenyl)-1H-indazole-5-carboxamide;
  - 3-(3-(2-(3-thienyl)acetylamino)phenyl)-1H-indazole-5-carboxamide;
  - 3-(3-(2-thienylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
  - 3-(3-(2-(4-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;
  - 3-(3-(2-(2-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;
  - 3-{3-(2-(4-fluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-(3-(cyclopropylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

- 3-{3-((3-hydroxyphenyl)carbonylamino)phenyl}-1H-indazole-5-carboxamide;
- 3-{3-(2-(2,4-dichlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
- 3-(3-{2-(4-(trifluoromethyl)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;
- 3-(3-{2-(4-(dimethylamino)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;
- 3-{3-(2-(2-chloro-4-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-{3-(2-(4-chlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-(3-(3-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;
  - 3-{3-(3-(4-fluorophenyl)propanoylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-{3-(2-(3,4-difluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-{3-(2-(2-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-(3-(2-phenylpropanoylamino)phenyl}-1H-indazole-5-carboxamide;
  - 3-(3-(2-piperidylethoxy)phenyl}-1H-indazole-5-carboxamide;
  - N-ethyl-3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino} propanamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-methoxypropyl)carboxamide;
  - 3-{3-(N-(2-piperidylethyl)carbamoyl)phenyl}-1H-indazole-5-carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxyethyl)carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxypropyl)carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(oxolan-2-ylmethyl)carboxamide;
  - 3-(2H, 3H-benzo(e)1,4-dioxin-6-yl)-1H-indazole-5-carboxamide;
  - 3-(3-quinolyl)-1H-indazole-5-carboxamide;
  - 3-(6-methoxy-2-naphthyl)-1H-indazole-5-carboxamide;
  - 3-(2,3-dihydrobenzo(b)furan-5-yl)-1H-indazole-5-carboxamide;
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-oxo-3-pyrrolidinylpropyl) carboxamide;
  - 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-methyl propanamide;
- 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N,N-dimethyl propanamide;
- 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-(2-methoxyethyl)propanamide; or a pharmaceutically acceptable salt thereof.

```
109.
              (Previously presented)
                                          A compound of claim 12, wherein the
compound is:
      phenyl-N-(3-phenyl(1H-indazol-5-yl))carboxamide;
      N-(3-phenyl(1H-indazol-5-yl))-2-pyridylcarboxamide;
       methyl 4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoate;
       4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoic acid;
       (2-hydroxyphenyl)-N-(3-phenyl(1H-indazol-5-yl)carboxamide;
       N-(3-(phenyl-1H-indazole-5-yl))acetamide;
       (4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;
       (3-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl)) (2-methylphenyl)carboxamide;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methoxyphenyl)carboxamide;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-phenylphenyl)carboxamide;
       benzo(b)thiophen-2-yl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
       methyl 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-pyridylcarboxamide;
       4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
       cyclopropyl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
       methyl 4-{N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoate;
       4-{N-(3-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoic acid;
       methyl 3-{N-((4-fluorophenyl)-1H-indazol-5-yl}carbamoyl}benzoate;
       3-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
       N-(3-(4-fluorophenyl)-(1H-indazol-5-yl))(4-(N-
methylcarbamoyl)phenyl)carboxamide;
       4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzamide;
       1-4-{N-(3-(4-methoxyphenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
       4-(N-(3-(4-pyridyl)-1H-indazol-5-yl)carbamoyl)benzoic acid;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl)benzamide;
       (3,4-bis(trifluoromethyl)phenyl)-N-(3-(4-fluorophenyl)(1H-indazol-5-
yl))carboxamide;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-furylcarboxamide;
       N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(3,4-dichlorophenyl)carboxamide;
```

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-hydroxyphenyl)carboxamide;

- N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4-pyridylcarboxamide;
- N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-pyridylcarboxamide;
- N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-thienylcarboxamide;
- N-(3-(4-fluorophenyl)(1H-indazol-5-yl))morpholin-4-yl-carboxamide;
- [N-(((2R)-2-hydroxycyclohexyl)methyl) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;] or a pharmaceutically acceptable salt thereof.
- 110. (Previously presented) A compound of claim 13, wherein the compound is:
  - (3-(4-fluorophenyl)(1H-indazol-5-yl))(4-pyridylmethyl)amine;
- (3-(4-fluorophenyl)(1H-indazol-5-yl))(3-pyridylmethyl)amine; or a pharmaceutically acceptable salt thereof.

## 111-113. (Canceled)

- 114. (Previously presented) A compound of claim 18, wherein the compound is:
  - 3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
  - 5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-methyl-4H-1,2,4-triazole;
  - 5-{3-(4-fluorophenyl)(1H-indazole-5-yl)]-3-(methylethyl)-4H-1,2,4-triazole;
  - 1-{5-(3-(4-fluorophenyl)-1H-indazole-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;
  - 5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-propyl-4H-1,2,4-triazole;
  - 5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;
  - 4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenol;
  - (4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)dimethylamine;
  - {2-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine;
  - 3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)furan;
  - 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;
  - 5-(3-naphthyl-1H-indazol-5-yl)-1H-1,2,4-triazole;
  - 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)thiophene;
  - 5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
  - 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenylamine;
  - 3-(3-(3,4-dichlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
  - 3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;
  - 3-(3-(4-methylphenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

```
N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)acetamide;
       5-(3-(3-chlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
       2-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfonyl)benzene;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfinyl)benzene;
       5-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;
       4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenylamine;
       5-{3-(4-(trifluoromethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl) (methylsulfonyl)amine;
      N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
       N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;
       N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;
       5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
       N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
       1-{5-{3-(4-fluorophenyl)1H-indazol-5-yl}-4H-1,2,4-Triazol-3-yl}ethan-1-ol;
       1-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl}-4H-1,2,4-triazol-3-yl}propan-2-ol;
       {3-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;
       {2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-yl-ethoxy)benzene;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-pyrrolidinylethoxy) benzene;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
       1-{2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethyl} pyrrolidin-2-
one;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperazinylethoxy) benzene;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(3-piperdylpropoxy) benzene;
       4-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}-1-
acetylpiperazine;
       2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethylamine;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-cyclohexylethoxy) benzene;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-
azaperhyroepinylethoxy)benzene;
       N-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furyl caroxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-benzyl caroxamide;
```

```
5-(3-(2-chlorophenyl)-1H-indazol-3-yl)-1H-1,2,4-triazole;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2,2-
dimehtylpropyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-
(cyclopropylmethyl)carboxamide;
       (3-(5-(1H-1,2,4-trizol-5-yl)(1H-indazol-3-yl))phenyl)-N-(3-
pyridylmethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-4-methyl piperazinyl ketone;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)
       carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-indan-2-ylcarboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-
((1R)indanyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-
((1S)indanyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S,2R)-2-
hydroxyindanyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((2S,1R)-2-
hydroxyindanyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1-methyl-1-
phenylethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(tert-butyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)-1-
phenylethyl)carboxamide;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl-isoindolin-2-yl ketone;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2-(dimethylamino)
ethyl)carboxamide;
       1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
       (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1R)indanyl benzene;
       {5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-(1,2,4)-triazol-3-ylmethyl}-dimethyl-
amine:
```

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxypropanamide; N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)butanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopropylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(6-chloro(3-

pyridyl))carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopentylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)benzo(b)thiophen-2-carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-furylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)isoxazol-5-ylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)pentanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-4-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-cyclohexylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-propanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-(4-fluorophenyl)acetic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)(2R)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)(2S)-2-hydroxy-2-phenylacetamide;

(2-{3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;

diethyl({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)amine;

({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)methylamine;

- ({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)} ethyl)dimethylamine;
- (2R)-N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;
- N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl)) phenyl)-3,3-dimethylbutanamide;
- N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-methylbutanamide;
- N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
- (3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;
- (3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3yl)}(1H-indazol-3-yl))phenyl)-N-((tert-butyl)methyl)carboxamide;
- ((1R)indanyl)(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)carboxamide;
- ({3-(3-(4-methoxyphenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;
- {(3-(3-(2H-benzo(d)1,3-dioxolen-5-yl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl}dimethylamine;
- (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;
- ((5-(3-benzo(D)furan-2-yl(1H-indazol-5-yl))(1H-1,2,4-triazol-3-yl))methyl)dimethylamine;
- (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-benzamide;
- (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(4-fluorophenyl)carboxamide-2HCl;
- (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-indan-2-yl-carboxamide;
- (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclopropylcarboxamide;

```
(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
N-cyclobutylcarboxamide-2HCl;
       1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(2-methoxyethoxy)benzene;
       1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(3-pyridylmethoxy)benzene;
       3-(5-(1H-1,2,4-triazol-3-y)-1H-indazol-3-yl)benzoic acid;
       3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid N-(4-(5-(1H-1,2,4-triazol-
3-yl)(1H-indazol-3-yl))phenyl)-2-(3-pyridyl)acetamide;
       N-(4-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-phenylacetamide;
       N-(4-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
       N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-
(dimethylamino)acetamide;
       (4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(methylsulfonyl)amine;
       (3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-N-(2-
methoxyethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-benzamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-
phenethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-
piperidylethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-morpholin-4-
ylethyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclohexylcarboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopentylcarboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-
fluorophenyl)carboxamide;
        (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-((1R,2R)-2-
phenylcyclopropyl) carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopropylcarboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(3-pyridyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(5,6,7,8-
tetrahydronaphthyl)carboxamide;
       (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzyl(4-
```

piperidyl))carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl-N-(1-benzylpyrrolidin-3-yl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(methylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclobutylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-pyridyl)carboxamide;

6-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2H,3h-benzo(e)1,4-dioxin;

6-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))-2-methoxynaphthalene;

3-(3-(3-quinoyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2,3-dihydrobenzo(b)furan;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2,4-dichlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)(4-methoxyphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)(4-methylphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)(4-chlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-morpholin-4-yl-acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-(4-methylpiperazinyl)acetamide;

2-methoxy-6-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}naphthalene;

N-phenyl(3-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}phenyl)carboxamide;

6-{5-(5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl}-2H,3H-benzo(e)1,4-dioxin; or a pharmaceutically acceptable salt thereof.

115. (Previously presented) A compound of claim 19, wherein the compound is:

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

```
5-(3-(3-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
       2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;
       5-{3-(4-(methylethyl)phenyl)-1H-indazol-5-yl}-2H-1,2,3,4-tetrazole;
       2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)furan;
       3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenylamine;
       5-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;
       3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;
       5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;
       1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;
       1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-methylpropoxy)benzene;
       5-(3-(4-chlorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
       1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-3-methoxybenzene;
       5-(3-(4-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
       2-(5-(2H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;
       2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;
       3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;
       5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;
       5-(3-(2-phenylethyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
       N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
       2-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;
       1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-morpholin-4-
ylethoxy)benzene;
       N-(3-(5-2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)2-phenoxypropanamide;
       N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-
piperidylpropanamide;
       N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;
       1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-
ylethoxy)benzene;
       4-(5-(2H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-1,2-dimethoxybenzene;
       N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-
methoxypropanamide;
       N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
```

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-2-methoxybenzene;

{3-(4-(5-(1H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;

{3-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;

{2-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine; N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxypropanamide;

N-(4-(5-(2H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide; or a pharmaceutically acceptable salt thereof.

116. (Previously presented) A compound of claim 20, wherein the compound is:

3-(4-fluorophenyl)-5-imidazol-2-yl-1H-indazole, or a pharmaceutically acceptable salt thereof.

117. (Previously presented) A compound, wherein the compound is:

3-phenyl-5-(phenylmethoxy)-1H-indazole;

(3-(4-fluorophenyl)(1H-indazol-5-yl))(phenylsulfonyl)amine;

3-(4-fluorophenyl)-1H-indazole-5-carboxylate;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(phenylmethoxy)carboxamide;

3-(4-fluorophenyl)-1H-indazole-5-carbohydroxamic acid;

N-((tert-butoxy)carbonylamino) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;

N-amino(3-(4-fluorophenyl)(1 H-indazol-5-yl))carboxamide;

methyl-3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylate;

3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylic acid; or a pharmaceutically acceptable salt thereof.

118. (Currently amended) A compound, wherein the compound is:

ethyl 1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl}piperidine-4-carboxylate;

2-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}phenyl)methyl benzoate;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))((4-fluorophenyl)amino)carboxamide;

5-nitro-3-phenyl-1H-indazole;

5-amino-3-phenyl-1H-indazole;

N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} (phenylmethoxy) carboxamide;

N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl)phenoxy)ethyl}acetamide;

2E-N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-phenylprop-2-enamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl)-2-indol-3-yl-2-oxoacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)methane carboxylic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(2-furyl)-2-

oxoacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl)-2-oxo-2-phenylacetamide;

(3-(5-(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl))phenyl-N-{2-(1-benzyl(4-piperidyl))ethylcarboxamide;

 $(1S)-1-\{N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)$  carbamoyl $\}$  ethyl acetate;

or a pharmaceutically acceptable salt thereof.

119. (Currently amended) A compound, wherein the compound is:

3-phenyl-5-trifluoromethyl-1H-indazole;

5-methyl-3-phenyl-1H-indazole;

3-(4-fluorophenyl)-5-pyrazol-3-yl-1H-indazole;

5-benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole;

5-{3-(4-fluorophenyl)(1H-indazole-5-yl))-3-phenyl-4H-1,2,4-triazole;

2-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} furan;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(4-pyridyl)-4H-1,2,4-triazole;

3-(4-chlorophenyl)-5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4H-1,2,4-triazole;

5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-(4-nitrophenyl)-4H-1,2,4-triazole;

1-{5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl))-4-methoxybenzene;

4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}phenylamine;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-benzyl-4H-1,2,4-triazole;

2-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-phenyl-1,3,4-oxadiazole;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-methyl-1,3,4-oxadiazole;

ethyl (2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoate;

```
3-(3-(4-fluorophenyl)-1H-indazol-5-yl)propanoic acid;
5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(3-pyridyl)-4H-1,2,4-triazole;
       4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} phenol;
2-{5-(3-(4-fluorophenyl)1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}acetic acid;
       ethyl 3-{5-{3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propanoate;
       ethyl-4-{5-(3-(4-fluorophenŷl)-1H-indazol-5-yl}-4H-1,2,4-triazol-3-yl}butanoate;
       3-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} propanoic acid;
5-methyl-3-(4-fluorophenyl)-1H-indazole;
3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,2,4-oxadiazolin-5-one;
       3-(4-fluorophenyl)-5-(2-phenylethynyl)-1H-indazole;
       5-((1E)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;
       5-((1E)-2-(2-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;
       4-{(1E)-2-((3-(4-fluorophenyl)-1H-indazol-5-yl)vinyl}benzoic acid;
       5-((1E)-2-(3-nitrophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;
       5-((1Z)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;
       5-((1E)-2-(4-aminophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;
       5-((1E)-2-(4-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;
       (2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoic acid;
       5-(2-(3-aminophenyl)ethyl)-3-(4-fluorophenyl)-1H-indazole;
       4-{2-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethyl}benzoic acid;
       3-(4-fluorophenyl)-5-(2-(2-pyridyl)ethyl)-1H-indazole;
       3-(4-fluorophenyl)-5-(2-phenylethyl)-1H-indazole;
       1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-ol;
       4-(3-(4-fluorophenyl)-1H-indazole-5-yl)pyrimidine-2-ylamine;
       5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazole-3-yl-amine;
       1-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}methyl)piperidin-
4-ol;
       1-acetyl-4-({5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl)}methyl)
       piperazine;
       3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(piperidylmethyl)-1H-1,2,4-triazole;
       4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-
yl}methyl)morpholine;
```

```
4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;
```

1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;

(5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-3-yl)methan-1-ol;

3-(3-(4-fluorophenyl)(1H-indazol-3-yl))-5-((4-pyrrolidinylpiperidyl) methyl)-1H-1,2,4-triazole;

3-(3-((1E)-2-phenylvinyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

1-((1E)-2-(5-(1H-1,2,4-triazol-3-yl))((1H-indazol-3-yl))vinyl)-4-methoxybenzene;

3-{3-((1E)-2-(4-chlorophenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

3-{3-((1E)-2-(4-methylphenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-

yl}methyl)morpholine;

4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;

1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;

3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;

3-[3-((4-fluorophenyl)(1H-indazol-3-yl)]-5-[(4-pyrrolidinylpiperidyl)methyl]-1H-1,2,4-triazole;

5-(3-((1E)-2-phenylvinyl)-1H-indazole-5yl)-2H-1,2,3,4-tetrazole; or a pharmaceutically acceptable salt thereof.